roluperidone
Small moleculeexperimental
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. Pre-clinical findings provide evidence of the effect of roluperidone on brain-derived neurotrophic factor ("BDNF"), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning and memory. — Wikipedia
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT00861796)
Timeline
Indications
Mechanism of action
- Serotonin 2a (5-HT2a) receptorINHIBITOR
HTR2A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CN1CCC(CN2Cc3ccccc3C2=O)CC1)c1ccc(F)cc1- Mol. weight
- 366.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRoluperidone ↗
- ChEMBLCHEMBL4297605 ↗
Also known as
- cyr-101
- cyr-101
- cyr-101
- min-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06107803 | Phase 1 | Oct 13, 2023 | Minerva Neurosciences |
| NCT03397134 | Phase 3 | Dec 15, 2017 | Minerva Neurosciences |
| NCT03072056 | Phase 1 | Jan 9, 2017 | Biokinetic Europe Ltd, Minerva Neurosciences |
| NCT03038646 | Phase 1 | Nov 1, 2016 | Biokinetic Europe Ltd, Minerva Neurosciences |
| NCT02232529 | Phase 1 | Sep 1, 2014 | Minerva Neurosciences, Quotient |
| NCT00861796 | Phase 2 | Mar 1, 2008 | Cyrenaic Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minerva Neurosciences | For profit | 5 | 5 | 2 | 2014 |
| Biokinetic Europe Ltd | For profit | 2 | 0 | 1 | 2016 |
| Cyrenaic Pharmaceuticals | For profit | 1 | 1 | 1 | 2008 |
| Quotient | For profit | 1 | 0 | 1 | 2014 |
4 organizations
Page 1 / 1